Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings

BACKGROUND: Abacavir and rilpivirine are alternative antiretroviral drugs for treatment-naïve HIV-infected patients. However, both drugs are only recommended for the patients who have pre-treatment HIV RNA <100,000 copies/mL. In resource-limited settings, pre-treatment HIV RNA is not routinely pe...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:AIDS Res Ther
Main Authors: Kiertiburanakul, Sasisopin, Boettiger, David, Ng, Oon Tek, Van Kinh, Nguyen, Merati, Tuti Parwati, Avihingsanon, Anchalee, Wong, Wing-Wai, Lee, Man Po, Chaiwarith, Romanee, Kamarulzaman, Adeeba, Kantipong, Pacharee, Zhang, Fujie, Choi, Jun Yong, Kumarasamy, Nagalingeswaran, Ditangco, Rossana, Cuong, Do Duy, Oka, Shinichi, Sim, Benedict Lim Heng, Ratanasuwan, Winai, Ly, Penh Sun, Yunihastuti, Evy, Pujari, Sanjay, Ross, Jeremy L., Law, Matthew, Sungkanuparph, Somnuek
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2017
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5420083/
https://ncbi.nlm.nih.gov/pubmed/28484509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12981-017-0151-1
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים